In 2024, rising H. pylori infection rates, shifting dietary habits, and increased global healthcare spending are transforming peptic ulcer therapeutics. Our research team's market dynamics analysis underscores growing demand for innovative proton pump inhibitors (PPIs) and H2 receptor antagonists across North America, Europe and Asia-Pacific.
The Global peptic ulcer drugs market size is estimated to be valued at USD 37.22 Bn in 2025 and is expected to reach USD 49.33 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 4.1% from 2025 to 2032.
This market forecast underscores substantial Peptic Ulcer Drugs Market Opportunities as companies intensify R&D pipelines to address unmet clinical needs and support business growth.
This market report by our research team combines market research with detailed market insights into segments and forecast drivers for business growth.
Market Drivers
- Surging H. pylori Infection Rates: According to WHO's 2024 data and our Peptic Ulcer Drugs Market report, over 50% of adults globally carry H. pylori, driving peptic ulcer drug demand.
- Innovative PPI and H2RA Development: Takeda's Vonoprazan achieved USD 120 Mn revenue in Japan (2024), reflecting rapid uptake and business growth.
- Expanding Geriatric Population: By 2025, individuals aged 65+ will represent 18% of the global population, intensifying peptic ulcer treatment requirements.
- Rising Healthcare Expenditure: Global health budgets grew by 5.3% in 2024, creating market opportunities for premium ulcer therapies.
PEST Analysis
- Political: In 2024, FDA accelerated approval pathways under Project Orbis expanded regulatory scope, slashing time-to-market for novel ulcer drugs.
- Economic: China's healthcare spending grew by 8% in 2024, enhancing industry size and investment influx; domestic producers commanded roughly 30% industry share, reflecting broader industry trends toward generic adoption.
- Social: A 2025 survey reported 30% of European seniors experience gastric reflux, driving patient demand and creating distinct market segments.
- Technological: AI-driven drug discovery platforms in 2025 reduced R&D timelines by 20%, fostering market innovation and enhancing market growth strategies.
Emerging peptic ulcer drugs market trends include digital therapeutics integration and personalized medicine adoption, promising improved patient outcomes.
Promotion and Marketing Initiative
- Takeda's 2025 “Gut Harmony” digital outreach in North America integrated patient education hubs, boosting prescription queries by 25% and mitigating market challenges and market restraints related to low awareness.
Key Players
Below is a list of prominent market companies shaping the competitive landscape:
- Daewoong Pharmaceutical Co., Ltd.
- Takeda Pharmaceutical Co., Ltd.
- Pfizer Inc.
- AstraZeneca plc
- Novartis AG
- Johnson & Johnson
- Sun Pharmaceutical Industries Ltd.
- Cipla Inc.
- Lupin Ltd.
- Dr. Reddy's Laboratories Ltd.
- Viatris Inc.
- GlaxoSmithKline plc
- Mylan (Viatris)
- Sandoz (Novartis)
- Ferring Pharmaceuticals
Recent Strategies
- Daewoong expanded its South Korea facility in 2024, elevating output by 20% and reinforcing its peptic ulcer drugs market share in APAC.
- Takeda launched Vonoprazan in the US in Q2 2025, generating USD 120 Mn in initial-year peptic ulcer drugs market revenue and reinforcing its global growth.
- Pfizer partnered with a digital health start-up in 2025 to deploy AI adherence tools, achieving a 15% uptick in patient engagement and business growth.
FAQs
1. Who are the dominant players in the Peptic Ulcer Drugs Market?
- Key players include Daewoong Pharmaceutical, Takeda, Pfizer, AstraZeneca, Novartis, Johnson & Johnson, Sun Pharma, Cipla, Lupin, Dr. Reddy's, Viatris, GSK, Mylan, Sandoz and Ferring.
2. What will be the size of the Peptic Ulcer Drugs Market in the coming years?
- The Global peptic ulcer drugs market size is projected to grow from USD 37.22 Bn in 2025 to USD 49.33 Bn by 2032 at a CAGR of 4.1%.
3. Which end-user segment has the largest growth opportunity?
- Hospital pharmacies and ambulatory care centers lead demand, driven by increasing inpatient procedures and outpatient ulcer management programs.
4. How will market development trends evolve over the next five years?
- Trends will include AI-enabled drug discovery, digital adherence platforms, personalized dosing regimens and greater generic penetration in emerging markets.
5. What is the nature of the competitive landscape and challenges in the Peptic Ulcer Drugs Market?
- The landscape is fragmented, with patent expirations, pricing pressures and reimbursement constraints posing key challenges despite strong R&D pipelines.
6. What go-to-market strategies are commonly adopted in the Peptic Ulcer Drugs Market?
- Companies leverage digital education campaigns, strategic partnerships, localized manufacturing expansions and value-based contracting to drive market penetration and revenue.
Get this report in Japanese Language – 消化性潰瘍治療薬市場
Get this report in Korean Language – 소화성 궤양 치료제 시장
Read More Blog Related to this Industry:-
Major Players - Diabetic Foot Ulcers Treatment Industry
Top Companies - Mouth Ulcers Treatment Industry
About Author
Alice Mutum is a seasoned senior content editor at Coherent Market Insights, leveraging extensive expertise gained from her previous role as a content writer. With seven years in content development, Alice masterfully employs SEO best practices and cutting-edge digital marketing strategies to craft high-ranking, impactful content. As an editor, she meticulously ensures flawless grammar and punctuation, precise data accuracy, and perfect alignment with audience needs in every research report. Alice's dedication to excellence and her strategic approach to content make her an invaluable asset in the world of market insights.
(LinkedIn: www.linkedin.com/in/alice-mutum-3b247b137)
